Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis-Reference-Cited by-同舟云学术

Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis

Published:2016-03 Issue:3 Volume:27 Page:390-397
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Fleury I.,Chevret S.,Pfreundschuh M.,Salles G.,Coiffier B.,van Oers M.H.J.,Gisselbrecht C.,Zucca E.,Herold M.,Ghielmini M.,Thieblemont C.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/27/3/390/6678292/mdv616.pdf

Reference29 articles.

1. Cancer statistics;Siegel;CA Cancer J Clin.,2014

2. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma;Coiffier;N Engl J Med,2002

3. Anti-CD20 monoclonal antibodies: beyond B-cells;Avivi;Blood Rev,2013

4. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group;Pfreundschuh;Lancet Oncol,2011

5. Addition of Rituximab Improves outcome of HIV negative patients with Burkitt lymphoma treated with the Lmba Protocol: results of the randomized intergroup (GRAALL-Lysa) LMBA02;Ribrag;Blood,2012

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Melanoma as Subsequent Primary Malignancy in Hematologic Cancer Survivors—A Literature Review;Journal of Clinical Medicine;2024-08-01

2. Biologics Versus JAK Inhibitors. Part I: Cancer Risk. A Narrative Review;Dermatology and Therapy;2024-05-19

3. Anticancer therapy-induced adverse drug reactions in children and preventive and control measures;Frontiers in Pharmacology;2024-02-15

4. Treatment-specific risk of subsequent malignant neoplasms in five-year survivors of diffuse large B-cell lymphoma;ESMO Open;2024-02

5. Highly Effective Therapy Versus Escalation Approaches in Early Multiple Sclerosis;Neurologic Clinics;2024-02